Journal of Cardiac Failure
Volume 12, Issue 6 , Pages 464-472 , August 2006

The Impact of Coenzyme Q10 on Systolic Function in Patients With Chronic Heart Failure

  • Stephen Sander, PharmD

      Affiliations

    • From the University of Connecticut School of Pharmacy, Storrs, Connecticut
    • Division of Drug Information, Hartford Hospital, Hartford, Connecticut
    • ,
  • Craig I. Coleman, PharmD

      Affiliations

    • From the University of Connecticut School of Pharmacy, Storrs, Connecticut
    • Division of Drug Information, Hartford Hospital, Hartford, Connecticut
    • ,
  • Aarti A. Patel, PharmD, MBA

      Affiliations

    • From the University of Connecticut School of Pharmacy, Storrs, Connecticut
    • Division of Drug Information, Hartford Hospital, Hartford, Connecticut
    • ,
  • Jeffrey Kluger, MD

      Affiliations

    • Division of Cardiology, Hartford Hospital, Hartford, Connecticut
    • ,
  • C. Michael White, PharmD

      Affiliations

    • From the University of Connecticut School of Pharmacy, Storrs, Connecticut
    • Division of Drug Information, Hartford Hospital, Hartford, Connecticut
    • Corresponding Author InformationReprint requests: Dr. C. Michael White, PharmD, Department of Pharmacy Practice, University of Connecticut, 69 North Eagleville Road, Storrs, CT 06269.

Received 27 October 2005 ,Revised 31 January 2006 ,Accepted 17 March 2006.

References 

  1. Blendon RJ, DesRoches CM, Benson JM, Brodie M, Altman DE. Americans' views on the use and regulation of dietary supplements. Arch Intern Med. 2001;161:805
  2. Shekelle P, Morton S, Hardy M. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease. Evidence Report/Technology Assessment No. 83 (Prepared by Southern California–RAND Evidence-based Practice Center, under Contract No 290-97-0001). AHRQ Publication No. 03-E043. Rockville, MD: Agency for Healthcare Research and Quality; 2003;
  3. Folkers K. Perspectives from research on vitamins and hormones. J Chem Educ. 1984;61:747–756
  4. Freeman L, Roubenoff R. The nutrition implications of cardiac cachexia. Nutr Rev. 1994;52:340–347
  5. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A. 1985;82:901–904
  6. Baggio E, Gandini R, Plancher AC, Passeri M, Carmosino G. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Molec Aspects Med. 1994;15(Suppl):S287–S294
  7. Rengo F, Abete P, Landino P, Leosco D, Covelluzzy F, Vitale D, et al. Role of metabolic therapy in cardiovascular disease. Clin Investig. 1993;71(Suppl):S124–S128
  8. Sacher HL, Sacer ML, Landau SW, Kersten R, Dooley F, Sacher A, et al. The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy. Am J Ther. 1997;4:66–72
  9. Langsjoen PH, Folkers K, Lyson K, Muratsu K, Lyson T, Lansjoen P. Effective and safe therapy with coenzyme Q10 for cardiomyopathy. Klin Wochenshr. 1988;66:583–590
  10. Langsjoen PH, Langsjoen PH, Folders K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1990;65:521–523
  11. Langsjoen PH, Lansjoen A, Willis R, Folkers K. Treatment of hypertrophic cardiomyopathy with Coenzyme Q10. Mol Aspect Med. 1997;S145–S151
  12. Soongswang J, Sangtawesin C, Durongpisitkul K, Laohaprasitiporn D, Nana A, Punlee K, et al. The effect of coenzyme Q10 in idiopathic chronic dilated cardiomyopathy in children. Pediatr Cardiol. 2005;epub ahead of print
  13. Lampertico M, Comis S. Italian multicenter study on the efficacy and safety of coenzyme Q10 as adjuvant therapy in heart failure. Clin Investig. 1993;71:S129–S133
  14. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Molec Aspects Med. 1997;18:S159–S168
  15. Dickersin K, Scherer R, Lefebvre C. Systematic review: identifying relevant studies for systematic reviews. BMJ. 1994;309:1286–1291
  16. Rice JA. Mathematical statistics and data analysis. Belmont (MA): Duxbury Press; 1988;
  17. Follmann D, Elliot P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol. 1992;45:769–773
  18. Judy WV, Hall JH, Toth PD, Folkers K. Double-blind-double crossover study of coenzyme Q10 in heart failure. In:  Folkers K,  Yamamura Y editor. Biomedical and clinical aspects of coenzyme Q. Vol 5. Amsterdam: Elsevier; 1986;p. 315–323
  19. Permanetter B, Rossy W, Klein G, Weingartner F, Seidl KF, Blomer H. Ubiquinone (coenzyme q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J. 1992;13:1528–1533
  20. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Invest. 1993;71:134S–136S
  21. Rengo F, Abete P, Landino P, Leosco D, Covelluzzi F, Vitale D, et al. Role of metabolic therapy in cardiovascular disease. Clin Invest. 1993;71:124S–128S
  22. Witte KKA, Nikitin NP, Parker AC, von Haehling S, Volk HD, Anker SD, et al. The effect of micronutrient supplementation on quality of life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J. 2005;26:2238–2244
  23. Jeejeebhoy F, Keith M, Freeman M, Barr A, McCall M, Kurian R, et al. Nutritional supplementation with MyoVive repletes essential cardiac myocytes nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143:1092–1100
  24. Berman M, Erman A, Ben-Gal T, Dvir D, Georghiou GP, Stamler A, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004;27:295–299
  25. Schneeberger W, Muller-Steinwachs J, Anda LP, Fuchs W, Zilliken F, Lyson K, et al. A clinical double blind and crossover trial with coenzyme Q10 on patients with cardiac disease. In:  Folkers K,  Yamamura Y editor. Biomedical and clinical aspects of coenzyme Q. Vol 5. Amsterdam: Elsevier; 1986;p. 325–333
  26. Vanfraechem JHP, Picalausa C, Folkers K. Effects of CoQ10 on physical performance and recovery in myocardial failure. In:  Folkers K,  Yamamura Y editor. Biomedical and clinical aspects of coenzyme Q. Vol 5. Amsterdam: Elsevier; 1986;p. 371–377
  27. Hofman-Bang C, Rehnqvist N, Swedberg K, Wiklund I, Astrom H. Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. J Card Failure. 1995;1:101–107
  28. Langsjoen PH, Vadhanavikit S, Folkers K. Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme 10. Proc Natl Acad Sci U S A. 1985;82:4240–4244
  29. Morisco C, Nappi A, Argenziano L, Sarno D, Fonatana D, Imbriaco M, et al. Noninvasive evaluation of cardiac hemodynamics during exercise in patients with chronic heart failure: effects of short-term coenzyme Q10 treatment. Molec Aspects Med. 1994;15:s155–s163
  30. Poggesi L, Galanti G, Comeglio M, Toncelli L, Vinci M. Effect of coenzyme Q10 on left ventricular function in patients with dilative cardiomyopathy. Current Therapeutic Research. 1991;49:878–886
  31. Serra G, Lissoni F, Piemonti C, Mazzola C. Evaluation of coenzyme Q10 in patients with moderate heart failure and chronic stable effort angina. In:  Folkers K,  Yamamura Y editor. Biomedical and clinical aspects of coenzyme Q. Vol 6. Amsterdam: Elsevier; 1991;p. 327–338
  32. Watson PS, Scalia GM, Galbraith A, Burstow DJ, Bett N, Aroney CN. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Card. 1999;33:1549–1552
  33. Keogh A, Fenton S, Leslie C, Aboyoun C, Macdonald P, Zhao YC, et al. Randomized double-blind, placebo-controlled trial of coenzyme Q10 therapy in class II and III systolic heart failure. Heart, Lung Circulation. 2003;12:135–141
  34. Khatta M, Alexander BS, Krichten CM, Fisher ML, Freudenberger R, Robinson SW, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636–640
  35. Munkholm H, Hansen HHT, Rasmussen K. Coenzyme Q10 treatment in serious heart failure. BioFactors. 1999;9:285–289
  36. Halsted CH. Dietary supplements and functional foods: 2 side of a coin?. Am J Clin Nutr. 2003;77(suppl):1001S–1007S
  37. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of morality. Am J Cardiol. 1988;62:25A–30A
  38. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B, et al. Predictors of total mortality and sudden death in mild to moderate heart failure, Captopril-Dixogin Study Group. J Am Coll Cardiol. 1989;14:564–570
  39. van Campen LCMC, Visser FC, Visser CA. Efection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Card Pharmacol. 1999;32:S31–S35
  40. Folkers K. Perspectives from research on vitamins and hormones. J Chem Educ. 1984;61:747–756
  41. Van den Heuvel AFM, Van Veldhuisen DJ, Van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2000;35:19–28
  42. Hodgson JM, Watts GF. Can coenzyme Q10 improve vascular function and blood pressure? Potential or effective therapeutic in vascular oxidative stress. Biofactors. 2003;18:129–136
  43. McCarty MF. Caoenzyme Q versus hypertension: does CoQ decrease endothelial superoxide generation?. Med Hypoth. 1999;53:300–304
  44. Forsmard-Andree P, Lee CP, Dallner G, Ernster L. Lipid peroxidation and changes in the ubiquinone content and the respiratory chain enzymes of submitochondrial particles. Free Radical Biol Med. 1997;22:391–400
  45. Pacher P, Schulz R, Liaudet L, Szabo C. Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmac Sci. 2005;26:302–310
  46. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative stress during myocardial ischaemia and heart failure. Curr Pharm Des. 2004;10:1699–1711
  47. Yamagami T, Takagi M, Adagami H. Effect of coenzyme Q10 on essential hypertension, a double-blind controlled study. In:  Folkers K,  Yamamura Y editor. Biomedical and clinical aspects of coenzyme Q. Vol 5. Amsterdam: Elsevier; 1986;p. 337–343
  48. Sing RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressure and insulin resistance in hypertensive patients with coronary artery disease. J Human Hypertension. 1999;13:203–208
  49. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr. 2002;56:1137–1142
  50. Burke BE, Neuenschwander R, Olson RD. Randomized, double-blind, placebo controlled trial of coenzyme Q10 in isolated systolic hypertension. Southern Med J. 2001;94:1112–1117
  51. Digiesi V, Cantini F, Brodbeck B. Effect of coenzyme Q10 on essential arterial hypertension. Curr Ther Res. 1990;47:841–845
  52. Digiesi V, Cantini F, Oradei A, Bisi G, Guarino GC, Brocchi A, et al. Mechanism of action of coenzyme Q10 in essential hypertension. Curr Ther Res. 1992;51:668–672
  53. Stafford RS, Radley DC. The underutilization of cardiac medications with proven benefit, 1990 to 2002. JACC. 2003;41:56–61

PII: S1071-9164(06)00169-2

doi: 10.1016/j.cardfail.2006.03.007

Journal of Cardiac Failure
Volume 12, Issue 6 , Pages 464-472 , August 2006

Article Tools

* Image Usage & Resolution